-->
A 40 year old healthy male presents to the cardiology clinic. He has been diligent about exercising regularly due to his family history of heart disease.
Patient: “My dad died of a heart attack while playing tennis at age 61 and he was really fit and I don’t want that to happen to me. So, I got a Calcium CT scan and my CAC score is 32. Is that bad, because it says it’s just mild?”
Cardiologist: “It’s pretty low, so we don’t need to worry about it yet. Let’s keep an eye on it.”
Patient: “But I went to this website called Multi-Ethnic Study of Atherosclerosis and plugged it into this Calcium Calculator and even if I were 45 I’d be at the 89th percentile rank. That sounds bad. Shouldn’t I do something about that now?”
A 62 year old female presents to the cardiology clinic. She has been an avid triathlete out of concern for her family history of heart disease.
Patient: “My mother died of a massive heart attack at 62 so I decided I should get one of those screening Calcium CT scans. I was shocked but not surprised when it came back super high at 1300! I should’ve known it’s in my genes. I’m really scared but I really don’t want to take any drugs. I prefer a natural approach.”
Cardiologist: “I don’t believe in those scores. There’s never been a randomized controlled trial showing any benefit to a calcium score. Are you having any symptoms, like chest pain?”
Patient: No.
Cardiologist: “Don’t worry about it. Your cholesterol ratio looks great! (What's Your ApoB? A Practical Approach to Lipid Management). Check out my supplements on the way out - I just restocked the Vitamin K2 and that’ll help the calcification you’re worried about. Effects of Vitamin K2 and D Supplementation on Coronary Artery Disease in Men: A RCT | JACC: Advances. By the way, when’s your next triathlon? Killer Workouts - The Adult Athlete
Why do these cases go undertreated?
While a low calcium score may impart low short term risk in an elderly patient, for instance, it may represent high lifetime risk in a young person (> 75th percentile for age, gender, race); placing them on a high risk trajectory for ASCVD complication to include cardiovascular death over the next, say, 30 years.
Sadly, many young patients with a “low CAC score,” but high percentile rank (>75th), have been misinformed to simply “keep an eye on it” because it’s “not high yet.” That’s not good advice, considering we know that the earlier we initiate intense treatment, the more likely we are to get in front of the disease and prevent a lifetime of ASCVD complications.
Coronary artery calcium scores carry a “warranty” of about 5-10 years. The Agatston score informs upon an individual’s near-term, or 10 year cardiovascular risk.
However, when compared to others of the same age, gender and race, it also provides a percentile rank and informs us of one’s “lifetime” risk, or “30-year” risk.
Many facilities use the risk calculator programmed into the CT scanner, which is often outdated and underestimates risk. MESA Calcium Calculator is preferred.
After decades of needless controversy, corruption and conspiracy (Watch The Widowmaker | Prime Video), multiple guidelines have finally embraced coronary artery calcium scores as part of the ASCVD risk stratification process. Tragically, there are many providers, to include specialists like cardiologists, who remain unconvinced, still holding out for some sort of RCT before embracing this technology that allows one to actually “see” the disease within the coronaries.
Long standing endurance athletes have been identified as a subgroup that may have a predilection for higher coronary artery calcium scores. This may in part explain the seemingly paradoxical phenomenon of sudden cardiac death during endurance races. Athletes may have a false sense of optimal health (healthy athlete bias) and either fail to obtain proper screening, or feel they can treat it solely through natural means - like “running” away from it. See Killer Workouts - The Adult Athlete.
In other cases a high CAC score may give some patients a false sense of doom, causing them to perhaps even withdraw from optimal medical therapy due to the belief that nothing can be done, or that “it’s in my genes - everyone in my family had this.” Many patients read the report and falsely conclude that they are destined to have a heart attack. Comments like “it says here I have a 99% chance of having a heart attack in 10 years” are not uncommon.
It’s important to communicate that no CAC score or percentile rank “guarantees” or “obligates” a person to having a future heart attack or stroke, but it does put them in good company with those who do when nothing is done about it. It is not a time to feel depressed about the diagnosis, but a time to feel fortunate that the diagnosis has been made before an ASCVD event has occurred knowing we have safe and effective therapies proven to halt and even regress atherosclerosis.
A checklist of targeted recommendations based on published guidelines
CardiAwareness Advocate Checklist:
Going into detail on the evidence behind the recommendations and history of treatment for this phenotype.
It’s a non-contrast computed tomography (CT) scan using MDCT (previously EBT) to scan the chest with high resolution gated imaging to search for and quantify the presence of coronary artery calcium (CAC) deposits.
Dr. Arthur Agatston (The Agatston Center) first described this technology as an effective tool for cardiovascular risk assessment in 1990 (Quantification of coronary artery calcium using ultrafast computed tomography - ScienceDirect).
CAC provides independent incremental information for predicting all-cause mortality in addition to traditional risk factors by the extent and the number of vascular territories involved (1 vs 3 vessel involvement, for instance) Long-Term Prognosis Associated With Coronary Calcification: Observations From a Registry of 25,253 Patients
Testing for the presence of coronary artery calcification by way of a non-contrast CT scan with Agatston score is appropriate for adults at intermediate risk as well as low risk individuals with a family history of premature heart disease. It allows for more personalized risk assessment, rather than extrapolating population data composed of risk factors to the individual.
The 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines recommends the selective use of CACscoring in primary prevention to aid in the decision-making process regarding statin therapy when there is uncertainty on the part of the clinician or patient.